GlaxoSmithKline Receives Underperform Rating from Credit Suisse (GSK)
GlaxoSmithKline (LON:GSK)‘s stock had its “underperform” rating reaffirmed by Credit Suisse in a research note issued on Thursday, Analyst Ratings Network.com reports. They currently have a GBX 1,500 ($24.26) target price on the stock. Credit Suisse’s price objective indicates a potential downside of 6.51% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group reiterated a “hold” rating on shares of GlaxoSmithKline in a research note to investors on Wednesday. They now have a GBX 1,600 ($25.87) price target on the stock. Separately, analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Wednesday. They now have a GBX 1,870 ($30.24) price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Tuesday. They now have a GBX 1,900 ($30.72) price target on the stock. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of GBX 1,630.52 ($26.37).
Shares of GlaxoSmithKline (LON:GSK) traded up 0.47% during mid-day trading on Thursday, hitting GBX 1604.50. 8,907,243 shares of the company’s stock traded hands. GlaxoSmithKline has a 52-week low of GBX 1314.00 and a 52-week high of GBX 1816.00. The stock’s 50-day moving average is GBX 1596. and its 200-day moving average is GBX 1649.. The company’s market cap is £77.738 billion.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.